• / Free eNewsletters & Magazine
  • / My Account
Home>Oncodesign: Business Update and FY 2016 Results

Oncodesign: Business Update and FY 2016 Results

3party Content

Thu, 30 Mar 2017

Oncodesign: Business Update and FY 2016 Results Profitable 2016 consolidated net income €9.6 million in net cash, compared with €9.2 million at year-end 2015 Clinical trial launched for the first radiotracer developed using Nanocyclix technology as part of the Imakinib project François Hyafil

©2017 Morningstar Advisor. All right reserved.